Click here to view online. Add this email to your safelist.
Updated durvalumab monotherapy data confirm results in urothelial bladder cancer
17 February 2017
AstraZeneca and its global biologics research and development arm, MedImmune, today announced updated efficacy and safety data for durvalumab in patients with locally-advanced or metastatic urothelial cancer (UC).
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
